EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieOpen Access

Bisoprolol in Patients With Chronic Obstructive Pulmonary Disease at High Risk of Exacerbation

Bisoprolol bei Patient:innen mit COPD und hohem Exazerbationsrisiko

Graham Devereux, Seonaidh Cotton, Mintu Nath, Nicola McMeekin, Karen Campbell, Rekha Chaudhuri, Gourab Choudhury, Anthony De Soyza, Shona Fielding, Simon Gompertz, John Haughney, Amanda J Lee und 11 weitere

JAMA · 13.08.2024 · 332 (6) · 462

DOI: 10.1001/jama.2024.8771 ↗

Auf einen Blick

In dieser randomisierten Studie senkte Bisoprolol die Zahl selbstberichteter COPD-Exazerbationen nicht gegenüber Placebo. Auch schwere unerwünschte Ereignisse unterschieden sich nicht klar.

Fragestellung

Verringert Bisoprolol bei COPD-Patient:innen mit hohem Exazerbationsrisiko die Zahl behandlungsbedürftiger Exazerbationen?

Methode

Doppelblinde placebokontrollierte randomisierte Studie an 76 UK-Standorten; Einschluss von COPD mit FEV 1/FVC <0,7 und ≥2 Exazerbationen in 12 Monaten; Follow-up bis 18. April 2023.

Ergebnisse

515 Patient:innen; primärer Endpunkt bei 514 verfügbar. Exazerbationen: 526 unter Bisoprolol, 513 unter Placebo; adjustierte IRR 0,97 (95 %-KI 0,84–1,13; P = .72). Schwere AE: 14,5 % vs. 14,3 %; RR 1,01 (95 %-KI 0,62–1,66).

Einschränkungen

Geplante Rekrutierung von 1574 Patient:innen wurde wegen der COVID-19-Pandemie unterbrochen; 371 (72,0 %) nahmen das Studienmedikament weiter ein.

Schlussfolgerung der Autor:innen

Bei COPD mit hohem Exazerbationsrisiko reduzierte Bisoprolol die Zahl der selbstberichteten Exazerbationen, die mit oralen Kortikosteroiden, Antibiotika oder beidem behandelt wurden, nicht.

Kernaussagen

  • Bisoprolol senkte die Exazerbationsrate nicht gegenüber Placebo.
  • IRR 0,97 (95 %-KI 0,84–1,13).
  • Schwere unerwünschte Ereignisse waren in beiden Gruppen ähnlich.

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Multizentrische Studie in der Zeitschrift JAMA, erschienen am 13.08.2024. Verfasst von Graham Devereux und 22 weiteren Autor:innen. Beteiligte Einrichtung: Liverpool School of Tropical Medicine, Liverpool, United Kingdom. Hauptthemen laut MEDLINE: Bisoprolol, Disease Progression, Pulmonary Disease, Chronic Obstructive. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. Observational studies report that β-blocker use may be associated with reduced risk of COPD exacerbations. However, a recent trial reported that metoprolol did not reduce COPD exacerbations and increased COPD exacerbations requiring hospital admission.

Objective

To test whether bisoprolol decreased COPD exacerbations in people with COPD at high risk of exacerbations. Design, Setting, and Participants The Bisoprolol in COPD Study (BICS) was a double-blind placebo-controlled randomized clinical trial conducted in 76 UK sites (45 primary care clinics and 31 secondary clinics). Patients with COPD who had at least moderate airflow obstruction on spirometry (ratio of forced expiratory volume in the first second of expiration [FEV 1 ] to forced vital capacity &lt;0.7; FEV 1 &lt;80% predicted) and at least 2 COPD exacerbations treated with oral corticosteroids, antibiotics, or both in the prior 12 months were enrolled from October 17, 2018, to May 31, 2022. Follow-up concluded on April 18, 2023.

Interventions

Patients were randomly assigned to bisoprolol (n = 261) or placebo (n = 258). Bisoprolol was started at 1.25 mg orally daily and was titrated as tolerated during 4 sessions to a maximum dose of 5 mg/d, using a standardized protocol. Main Outcomes and Measures The primary clinical outcome was the number of patient-reported COPD exacerbations treated with oral corticosteroids, antibiotics, or both during the 1-year treatment period. Safety outcomes included serious adverse events and adverse reactions.

Results

Although the trial planned to enroll 1574 patients, recruitment was suspended from March 16, 2020, to July 31, 2021, due to the COVID-19 pandemic. Two patients in each group were excluded postrandomization. Among the 515 patients (mean [SD] age, 68 [7.9] years; 274 men [53%]; mean FEV 1 , 50.1%), primary outcome data were available for 514 patients (99.8%) and 371 (72.0%) continued taking the study drug. The primary outcome of patient-reported COPD exacerbations treated with oral corticosteroids, antibiotics, or both was 526 in the bisoprolol group, with a mean exacerbation rate of 2.03/y, vs 513 exacerbations in the placebo group, with a mean exacerbation rate of 2.01/y. The adjusted incidence rate ratio was 0.97 (95% CI, 0.84-1.13; P = .72). Serious adverse events occurred in 37 of 255 patients in the bisoprolol group (14.5%) vs 36 of 251 in the placebo group (14.3%; relative risk, 1.01; 95% CI, 0.62-1.66; P = .96). Conclusions and Relevance Among people with COPD at high risk of exacerbation, treatment with bisoprolol did not reduce the number of self-reported COPD exacerbations requiring treatment with oral corticosteroids, antibiotics, or both. Trial Registration isrctn.org Identifier: ISRCTN10497306

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BisoprololDisease ProgressionPulmonary Disease, Chronic ObstructiveAgedFemaleHumansMaleMiddle AgedAdrenal Cortex HormonesAdrenergic beta-1 Receptor AntagonistsAnti-Bacterial AgentsDouble-Blind MethodForced Expiratory VolumePatient Reported Outcome Measures

Substanzen

Adrenal Cortex HormonesAdrenergic beta-1 Receptor AntagonistsAnti-Bacterial AgentsBisoprolol

Autor:innen und Institutionen

  • Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
  • Centre for Healthcare Randomised Trials (CHaRT), University of Aberdeen, Aberdeen, United Kingdom.
  • Liverpool University Hospitals Foundation NHS Trust, University Hospital Aintree, Liverpool, United Kingdom.
  • Medical Statistics Team, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, United Kingdom.
  • School of Health & Wellbeing, University of Glasgow, Glasgow, United Kingdom.
  • School of Infection & Immunity, University of Glasgow, Glasgow, United Kingdom.

Zitieren

APA

Devereux, G., Cotton, S., Nath, M., McMeekin, N., Campbell, K., Chaudhuri, R., Choudhury, G., De Soyza, A., Fielding, S., Gompertz, S., Haughney, J., Lee, A. J., MacLennan, G., Morice, A., Norrie, J., Price, D., Short, P., Vestbo, J., Walker, P., …, & Lipworth, B. J. (2024). Bisoprolol in Patients With Chronic Obstructive Pulmonary Disease at High Risk of Exacerbation. JAMA, 332(6), 462. https://doi.org/10.1001/jama.2024.8771

Vancouver

Devereux G, Cotton S, Nath M, McMeekin N, Campbell K, Chaudhuri R, et al. Bisoprolol in Patients With Chronic Obstructive Pulmonary Disease at High Risk of Exacerbation. JAMA. 2024;332(6):462. doi:10.1001/jama.2024.8771

BibTeX
@article{Devereux2024,
  author = {Devereux, Graham and Cotton, Seonaidh and Nath, Mintu and McMeekin, Nicola and Campbell, Karen and Chaudhuri, Rekha and Choudhury, Gourab and De Soyza, Anthony and Fielding, Shona and Gompertz, Simon and Haughney, John and Lee, Amanda J and MacLennan, Graeme and Morice, Alyn and Norrie, John and Price, David and Short, Philip and Vestbo, Jorgen and Walker, Paul and Wedzicha, Jadwiga and Wilson, Andrew and Wu, Olivia and Lipworth, Brian J},
  title = {Bisoprolol in Patients With Chronic Obstructive Pulmonary Disease at High Risk of Exacerbation},
  journal = {JAMA},
  year = {2024},
  volume = {332},
  number = {6},
  pages = {462},
  doi = {10.1001/jama.2024.8771}
}
Kostenlos starten →